TGFB1 and systemic sclerosis: On the contrary, nintedanib at the concentrations of 0.1 and 1μM significantly reduced the production and release of TGFβ1 only after 24 h of treatment compared to untreated cells in cultured MDMs from SSc-ILD patients (p < 0.05 for both concentrations) (Fig. 5).